RDHL Valuation
Redhill Biopharma Ltd
$
1.400
- Overview
- Forecast
- Valuation
- Earnings
RDHL Relative Valuation
RDHL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RDHL is overvalued; if below, it's undervalued.
Historical Valuation
Redhill Biopharma Ltd (RDHL) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.08 is considered Undervalued compared with the five-year average of -8.83. The fair price of Redhill Biopharma Ltd (RDHL) is between 4.48 to 36.37 according to relative valuation methord. Compared to the current price of 1.40 USD , Redhill Biopharma Ltd is Undervalued By 68.78%.
Relative Value
Fair Zone
4.48-36.37
Current Price：1.40
68.78%
Undervalued
0.02
PE
1Y
3Y
5Y
Trailing
Forward
-0.00
EV/EBITDA
Redhill Biopharma Ltd. (RDHL) has a current EV/EBITDA of -0.00. The 5-year average EV/EBITDA is -26.96. The thresholds are as follows: Strongly Undervalued below -323.61, Undervalued between -323.61 and -175.28, Fairly Valued between 121.37 and -175.28, Overvalued between 121.37 and 269.70, and Strongly Overvalued above 269.70. The current Forward EV/EBITDA of -0.00 falls within the Historic Trend Line -Fairly Valued range.
0.21
EV/EBIT
Redhill Biopharma Ltd. (RDHL) has a current EV/EBIT of 0.21. The 5-year average EV/EBIT is -11.95. The thresholds are as follows: Strongly Undervalued below -102.88, Undervalued between -102.88 and -57.41, Fairly Valued between 33.52 and -57.41, Overvalued between 33.52 and 78.98, and Strongly Overvalued above 78.98. The current Forward EV/EBIT of 0.21 falls within the Historic Trend Line -Fairly Valued range.
0.08
PS
Redhill Biopharma Ltd. (RDHL) has a current PS of 0.08. The 5-year average PS is 1.39. The thresholds are as follows: Strongly Undervalued below -0.80, Undervalued between -0.80 and 0.30, Fairly Valued between 2.48 and 0.30, Overvalued between 2.48 and 3.57, and Strongly Overvalued above 3.57. The current Forward PS of 0.08 falls within the Undervalued range.
-1.53
P/OCF
Redhill Biopharma Ltd. (RDHL) has a current P/OCF of -1.53. The 5-year average P/OCF is -5.92. The thresholds are as follows: Strongly Undervalued below -28.83, Undervalued between -28.83 and -17.38, Fairly Valued between 5.53 and -17.38, Overvalued between 5.53 and 16.98, and Strongly Overvalued above 16.98. The current Forward P/OCF of -1.53 falls within the Historic Trend Line -Fairly Valued range.
-0.33
P/FCF
Redhill Biopharma Ltd. (RDHL) has a current P/FCF of -0.33. The 5-year average P/FCF is -1.61. The thresholds are as follows: Strongly Undervalued below -6.13, Undervalued between -6.13 and -3.87, Fairly Valued between 0.64 and -3.87, Overvalued between 0.64 and 2.90, and Strongly Overvalued above 2.90. The current Forward P/FCF of -0.33 falls within the Historic Trend Line -Fairly Valued range.
Redhill Biopharma Ltd (RDHL) has a current Price-to-Book (P/B) ratio of -0.35. Compared to its 3-year average P/B ratio of 55.55 , the current P/B ratio is approximately -100.63% higher. Relative to its 5-year average P/B ratio of 36.10, the current P/B ratio is about -100.97% higher. Redhill Biopharma Ltd (RDHL) has a Forward Free Cash Flow (FCF) yield of approximately -321.71%. Compared to its 3-year average FCF yield of -296.45%, the current FCF yield is approximately 8.52% lower. Relative to its 5-year average FCF yield of -191.39% , the current FCF yield is about 68.09% lower.
-0.35
P/B
Median3y
55.55
Median5y
36.10
-321.71
FCF Yield
Median3y
-296.45
Median5y
-191.39
Competitors Valuation Multiple
The average P/S ratio for RDHL's competitors is 0.04, providing a benchmark for relative valuation. Redhill Biopharma Ltd Corp (RDHL) exhibits a P/S ratio of 0.08, which is 99.12% above the industry average. Given its robust revenue growth of -90.21%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of RDHL increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of RDHL in the past 1 year is driven by Unknown.
People Also Watch
PAVM
PAVmed Inc
0.471
USD
+6.56%
IPDN
Professional Diversity Network Inc
2.180
USD
-2.68%
PNBK
Patriot National Bancorp Inc
1.630
USD
-1.81%
TGL
Treasure Global Inc
1.210
USD
+6.14%
ABVC
ABVC Biopharma Inc
2.970
USD
+1.02%
ULY
Urgent.ly Inc
5.060
USD
-0.39%
CTNT
Cheetah Net Supply Chain Service Inc
1.710
USD
-2.68%
GURE
Gulf Resources Inc
0.629
USD
-0.94%
BLMZ
Harrison Global Holdings Inc
0.183
USD
-5.67%
FAQ
Is Redhill Biopharma Ltd (RDHL) currently overvalued or undervalued?
Redhill Biopharma Ltd (RDHL) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.08 is considered Undervalued compared with the five-year average of -8.83. The fair price of Redhill Biopharma Ltd (RDHL) is between 4.48 to 36.37 according to relative valuation methord. Compared to the current price of 1.40 USD , Redhill Biopharma Ltd is Undervalued By 68.78% .
What is Redhill Biopharma Ltd (RDHL) fair value?
How does RDHL's valuation metrics compare to the industry average?
What is the current P/B ratio for Redhill Biopharma Ltd (RDHL) as of Aug 13 2025?
What is the current FCF Yield for Redhill Biopharma Ltd (RDHL) as of Aug 13 2025?
What is the current Forward P/E ratio for Redhill Biopharma Ltd (RDHL) as of Aug 13 2025?